alopecia

Posts

Global Alopecia Treatment Market

Androgenetic Alopecia Treatment Market

Androgenetic Alopecia Treatment Market Analysis

Androgenetic alopecia (AGA) is a patterned hair loss occurring due to systemic androgen and genetic factors. It is the most common cause of hair loss in both genders. It is characterized by follicular miniaturization in a patterned hair loss occurring due to systemic androgen and genetic factors. The increasing incidence of androgenetic alopecia is expected to boost the market growth.

According to the National Center for Biotechnology Information (NCBI), in August 2015, the global prevalence of severe androgenetic alopecia (AGA) was 15.33% overall and varied significantly by geographical region. The risk of having severe androgenetic alopecia (AGA) increased by 1.092 for per year for the 30 and 40 age group.

The global androgenetic alopecia treatment market is estimated to be valued at US$ 1,607.47 million in 2020 and is expected to exhibit a CAGR of 5.2% during the forecast period (2020-2027).

Product development and ongoing clinical trials are expected to propel the growth of the global androgenetic alopecia treatment market.

Development of drugs for androgenetic alopecia treatment is expecting to boost the market growth over the forecast period. For instance, Cairo University is conducting a clinical trial of topical Cetirizine for the treatment of androgenetic alopecia in females.

The trial is in Phase II/III evaluating the efficacy and tolerability of topical cetirizine in female patients with androgenetic alopecia (AGA). This interventional trial started in February 2020 and the study expected completed in December 2021.

However, side effects of androgenetic alopecia treatment are expected to hinder the market growth. According to the US Pharmacist, a clinically-focused pharmacy publication, published an article- Treatment Options for Androgenetic Alopecia, in 2018 that medication used in for the treatment of androgenetic alopecia has many side effects. For example, topical Minoxidil can cause local erythema and pruritus and Finasteride can cause dizziness, orthostatic hypotension and others.

Report Coverage Details

Base Year:
2019

Market Size in 2020:
US$ 1,607.47 Mn

Historical Data for:
2016 to 2019

Forecast Period:
2020 to 2027

Forecast Period 2020 to 2027 CAGR:
5.3%

2027 Value Projection:
US$ 2,298.34 Mn

Geographies covered:

  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa

Segments covered:

  • By Drug Type: Topical Agents, 5 AR Inhibitors, Others.
  • By Route of Administration: Oral, Topical.
  • By Gender: Male, Female.
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.

Companies covered:

Histogen Inc., Cipla Limited, Aclaris Therapeutics, Inc., Merck & Co., Inc., Daiichi-Sankyo Co., Ltd., Johnson and Johnson Services, Inc., Lexington International LLC, Vita-Cos-Med Klett-Loch GmbH, PureTech, Vitabiotics, Dr. Reddy’s Laboratories, HCell Inc., Follica, Inc. and Ranbaxy Laboratories Ltd.

Growth Drivers:

  • Rising incidence of androgenetic alopecia
  • Product development and ongoing trials for treatment of androgenetic alopecia

Restraints & Challenges:

  • Side effects of androgenetic alopecia treatment
  • Alternative treatment for androgenetic alopecia treatment

Research and development of treatment for androgenetic alopecia in North America is expected to boost the market growth.

North America is expected to hold dominant position in the global androgenetic alopecia treatment market owing to research and development of treatments for androgenetic alopecia in the region. For instance, on June 4, 2020, Follica, Inc., a biotechnology company developing a regenerative platform designed to treat androgenetic alopecia, and other related conditions, announced positive feedback from the U.S. Food and Drug Administration (FDA) for its FOL-004 Phase II released in December 2019. The company advanced its lead program, FOL-004 into Phase III development, following a successful safety and efficacy optimization study for the treatment of hair loss in male androgenetic alopecia.

Global Androgenetic Alopecia Treatment Market – Impact of Coronavirus (COVID-19) Pandemic

Nationwide lockdowns resulting from COVID-19 in various countries across the globe have impacted the financial status of businesses in all sectors. The private healthcare is one such sector which has been impacted significantly by the COVID-19 pandemic.

The lockdown in various countries due to the pandemic has placed an economic burden on the healthcare sector. Moreover, the coronavirus pandemic has hampered the development, production, and supply of drugs and other healthcare products and affected growth of healthcare businesses of various companies across the globe.

As a result, the impact of the COVID-19 pandemic is also expected to limit the growth of the global androgenetic alopecia treatment drugs market during the forecast period.

Key Players

Major players operating in the global androgenetic alopecia treatment market are Histogen Inc., Cipla Limited, Aclaris Therapeutics, Inc., Merck & Co., Inc., Daiichi-Sankyo Co., Ltd., Johnson and Johnson Services, Inc., Lexington International LLC, Vita-Cos-Med Klett-Loch GmbH, PureTech, Vitabiotics, Dr Reddy’s Laboratories, HCell Inc., Follica, Inc. and Ranbaxy Laboratories Ltd. among others.

Androgenetic Alopecia Treatment Market Analysis

Source

Recent Posts

Global Alopecia Treatment Market

Androgenetic Alopecia Treatment Market

Androgenetic Alopecia Treatment Market Analysis

Androgenetic alopecia (AGA) is a patterned hair loss occurring due to systemic androgen and genetic factors. It is the most common cause of hair loss in both genders. It is characterized by follicular miniaturization in a patterned hair loss occurring due to systemic androgen and genetic factors. The increasing incidence of androgenetic alopecia is expected to boost the market growth.

According to the National Center for Biotechnology Information (NCBI), in August 2015, the global prevalence of severe androgenetic alopecia (AGA) was 15.33% overall and varied significantly by geographical region. The risk of having severe androgenetic alopecia (AGA) increased by 1.092 for per year for the 30 and 40 age group.

The global androgenetic alopecia treatment market is estimated to be valued at US$ 1,607.47 million in 2020 and is expected to exhibit a CAGR of 5.2% during the forecast period (2020-2027).

Product development and ongoing clinical trials are expected to propel the growth of the global androgenetic alopecia treatment market.

Development of drugs for androgenetic alopecia treatment is expecting to boost the market growth over the forecast period. For instance, Cairo University is conducting a clinical trial of topical Cetirizine for the treatment of androgenetic alopecia in females.

The trial is in Phase II/III evaluating the efficacy and tolerability of topical cetirizine in female patients with androgenetic alopecia (AGA). This interventional trial started in February 2020 and the study expected completed in December 2021.

However, side effects of androgenetic alopecia treatment are expected to hinder the market growth. According to the US Pharmacist, a clinically-focused pharmacy publication, published an article- Treatment Options for Androgenetic Alopecia, in 2018 that medication used in for the treatment of androgenetic alopecia has many side effects. For example, topical Minoxidil can cause local erythema and pruritus and Finasteride can cause dizziness, orthostatic hypotension and others.

Report Coverage Details

Base Year:
2019

Market Size in 2020:
US$ 1,607.47 Mn

Historical Data for:
2016 to 2019

Forecast Period:
2020 to 2027

Forecast Period 2020 to 2027 CAGR:
5.3%

2027 Value Projection:
US$ 2,298.34 Mn

Geographies covered:

  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa

Segments covered:

  • By Drug Type: Topical Agents, 5 AR Inhibitors, Others.
  • By Route of Administration: Oral, Topical.
  • By Gender: Male, Female.
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.

Companies covered:

Histogen Inc., Cipla Limited, Aclaris Therapeutics, Inc., Merck & Co., Inc., Daiichi-Sankyo Co., Ltd., Johnson and Johnson Services, Inc., Lexington International LLC, Vita-Cos-Med Klett-Loch GmbH, PureTech, Vitabiotics, Dr. Reddy’s Laboratories, HCell Inc., Follica, Inc. and Ranbaxy Laboratories Ltd.

Growth Drivers:

  • Rising incidence of androgenetic alopecia
  • Product development and ongoing trials for treatment of androgenetic alopecia

Restraints & Challenges:

  • Side effects of androgenetic alopecia treatment
  • Alternative treatment for androgenetic alopecia treatment

Research and development of treatment for androgenetic alopecia in North America is expected to boost the market growth.

North America is expected to hold dominant position in the global androgenetic alopecia treatment market owing to research and development of treatments for androgenetic alopecia in the region. For instance, on June 4, 2020, Follica, Inc., a biotechnology company developing a regenerative platform designed to treat androgenetic alopecia, and other related conditions, announced positive feedback from the U.S. Food and Drug Administration (FDA) for its FOL-004 Phase II released in December 2019. The company advanced its lead program, FOL-004 into Phase III development, following a successful safety and efficacy optimization study for the treatment of hair loss in male androgenetic alopecia.

Global Androgenetic Alopecia Treatment Market – Impact of Coronavirus (COVID-19) Pandemic

Nationwide lockdowns resulting from COVID-19 in various countries across the globe have impacted the financial status of businesses in all sectors. The private healthcare is one such sector which has been impacted significantly by the COVID-19 pandemic.

The lockdown in various countries due to the pandemic has placed an economic burden on the healthcare sector. Moreover, the coronavirus pandemic has hampered the development, production, and supply of drugs and other healthcare products and affected growth of healthcare businesses of various companies across the globe.

As a result, the impact of the COVID-19 pandemic is also expected to limit the growth of the global androgenetic alopecia treatment drugs market during the forecast period.

Key Players

Major players operating in the global androgenetic alopecia treatment market are Histogen Inc., Cipla Limited, Aclaris Therapeutics, Inc., Merck & Co., Inc., Daiichi-Sankyo Co., Ltd., Johnson and Johnson Services, Inc., Lexington International LLC, Vita-Cos-Med Klett-Loch GmbH, PureTech, Vitabiotics, Dr Reddy’s Laboratories, HCell Inc., Follica, Inc. and Ranbaxy Laboratories Ltd. among others.

Androgenetic Alopecia Treatment Market Analysis

Source

Recent Posts

Alopecia Treatment Market

Global Alopecia Drugs Market Report

Global Alopecia Drugs Market Report

The Alopecia Drugs market is expected to grow from USD X.X million in 2020 to USD X.X million by 2026, at a CAGR of X.X% during the forecast period. The global Alopecia Drugs market report is a comprehensive research that focuses on the overall consumption structure, development trends, sales models and sales of top countries in the global Alopecia Drugs market.

The report focuses on well-known providers in the global Alopecia Drugs industry, market segments, competition, and the macro environment.

Under COVID-19 Outbreak, how the Alopecia Drugs Industry will develop is also analyzed in detail in Chapter 1.7 of the report.

In Chapter 2.4, we analyzed industry trends in the context of COVID-19.

In Chapter 3.5, we analyzed the impact of COVID-19 on the product industry chain based on the upstream and downstream markets.

In Chapters 6 to 10 of the report, we analyze the impact of COVID-19 on various regions and major countries.

In chapter 13.5, the impact of COVID-19 on the future development of the industry is pointed out.

A holistic study of the market is made by considering a variety of factors, from demographics conditions and business cycles in a particular country to market-specific microeconomic impacts. The study found the shift in market paradigms in terms of regional competitive advantage and the competitive landscape of major players.

Key players in the global Alopecia Drugs market covered in Chapter 4

Dr. Reddy’s Laboratories Ltd
Cipla Inc.
Aqua Pharmaceuticals
Bayer HealthCare
Merck
Helix BioMedix
The Himalaya Drug Company
GlaxoSmithKline
Johnson & Johnson
AndroScience

In Chapter 11 and 13.3, on the basis of types, the Alopecia Drugs market from 2015 to 2026 is primarily split into:_x000D_

Oral
Topical
Injectable

In Chapter 12 and 13.4, on the basis of applications, the Alopecia Drugs market from 2015 to 2026 covers:

Men
Women

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2015-2026) of the following regions are covered in Chapter 5, 6, 7, 8, 9, 10, 13:

North America (Covered in Chapter 6 and 13)
United States
Canada
Mexico
Europe (Covered in Chapter 7 and 13)
Germany
UK
France
Italy
Spain
Russia
Others
Asia-Pacific (Covered in Chapter 8 and 13)
China
Japan
South Korea
South America (Covered in Chapter 10 and 13)
Brazil
Argentina
Columbia
Chile
Others

Years considered for this report:

Historical Years: 2015-2019

Base Year: 2019

Estimated Year: 2020

Forecast Period: 2020-2026

Global Alopecia Drugs Market Report

Source

Recent Posts

Alopecia Treatment Market

Alopecia Market Size

Alopecia Market Size, Share, Trends, Growth, Forecast Analysis Report 2019 By Product, By Application, By Segment, By Region – Global Forecast To 2025

Up Market Research offers a latest published report on “Global Global Alopecia Market Research Report 2019 Market Research Report 2019” delivering key insights and providing a competitive advantage to clients through a detailed report. The report highly exhibits on current market analysis scenario, upcoming as well as future opportunities, revenue growth, pricing and profitability.

Global Alopecia Market Research Report 2019 Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period.

It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report. The report contains basic, secondary and advanced information pertaining to the Global Alopecia Market Research Report 2019 Market global status and trend, market size, share, growth, trends analysis, segment and forecasts from 2019 – 2026.

The report for Global Alopecia Market Research Report 2019 Market analysis & forecast 2019 – 2026 is segmented into Product Segment, Application Segment & Major players.

Region-wise Analysis Global Alopecia Market Research Report 2019 Market covers:

• North America
• Europe
• China
• Japan
• India
• Southeast Asia
• Other regions (Central & South America, Middle East & Africa)

The Global Alopecia Market Research Report 2019 Market Report can be segmented into Product Types and Applications.

The Report Covers In-Depth Analysis As Follows:

• Chapter 1 Overview of Global Alopecia Market Research Report 2019 Market
• Chapter 2 Global Market Status and Forecast by Regions
• Chapter 3 Global Market Status and Forecast by Types
• Chapter 4 Global Market Status and Forecast by Downstream Industry
• Chapter 5 Market Driving Factor Analysis of Global Alopecia Market Research Report 2019 Market
• Chapter 6 Global Alopecia Market Research Report 2019 Market Competition Status by Major Manufacturers
• Chapter 7 Global Alopecia Market Research Report 2019 Market Major Manufacturers Introduction and Market Data
• Chapter 8 Upstream and Downstream Market Analysis of Global Alopecia Market Research Report 2019 Market
• Chapter 9 Cost and Gross Margin Analysis of Global Alopecia Market Research Report 2019 Market
• Chapter 10 Marketing Status Analysis of Global Alopecia Market Research Report 2019 Market
• Chapter 11 Report Conclusion
• Chapter 12 Research Methodology and Reference

“Global Alopecia Market Research Report 2019 Market Analysis and Forecast 2019 – 2026” report helps the clients to take business decisions and to understand strategies of major players in the industry. The report also calls for market-driven results deriving feasibility studies for client needs. UpMarketResearch ensures qualified and verifiable aspects of market data operating in the real-time scenario. The analytical studies are conducted ensuring client needs with a thorough understanding of market capacities in the real-time scenario.

Global Alopecia Market Research Report 2019 Market: Key Stakeholders:

• Manufacturers
• Distributors/Traders/Wholesalers
• Subcomponent Manufacturers
• Industry Association
• Downstream Vendors

In this study, the years considered to estimate the market size of the Global Alopecia Market Research Report 2019 Market are as follows:

• History Year: 2013-2018
• Base Year: 2018
• Estimated Year: 2019
• Forecast Year 2019 to 2026

Key Reasons to Purchase:

• To gain insightful analyses of the market and have a comprehensive understanding of the “Global Alopecia Market Research Report 2019 Market” and its commercial landscape.
• Learn about the market strategies that are being adopted by your competitors and leading organizations.
• To understand the future outlook and prospects for Global Alopecia Market Research Report 2019 Market analysis and forecast 2019 – 2026.

Customization of the Report:

Up Market Research provides free customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

You can also ask for region wise market research report, as below:

• Global Alopecia Market Research Report 2019 Market – Global Market Status & Trend Report 2013- 2026 Top 20 Countries Data
• Global Alopecia Market Research Report 2019 Market – North America Market Status and Trend Report 2013- 2026
• Global Alopecia Market Research Report 2019 Market – South America Market Status and Trend Report 2013- 2026
• Global Alopecia Market Research Report 2019 Market – Europe Market Status and Trend Report 2013- 2026
• Global Alopecia Market Research Report 2019 Market – EMEA Market Status and Trend Report 2013- 2026
• Global Alopecia Market Research Report 2019 Market – Asia Pacific Market Status and Trend Report 2013- 2026
• Global Alopecia Market Research Report 2019 Market – China Market Status and Trend Report 2013- 2026
• Global Alopecia Market Research Report 2019 Market – India Market Status and Trend Report 2013- 2026

Alopecia Market Size, Share, Trends, Growth, Forecast Analysis Report 2019 By Product, By Application, By Segment, By Region – Global Forecast To 2025

Recent Posts

CTP-543 Phase 3 Trials in Alopecia Areata

CTP-543 Alopecia Areata

Concert Pharmaceuticals Announces CTP-543 Alopecia Areata Data Selected for Late-Breaker Oral Presentation at 2020 EADV Virtual Congress

Concert Pharmaceuticals today announced that it will present clinical data on CTP-543 for the treatment of alopecia areata as a late-breaker oral presentation at the 29th European Academy of Dermatology and Venereology (EADV) Virtual Congress. The meeting will be held virtually October 29-31, 2020.

The oral presentation will highlight new data from an ongoing open-label extension study evaluating long-term safety and treatment effects of CTP-543 in patients with moderate to severe alopecia areata.

The details of the presentation are as follows:

  • Title: Initial Results from a Long-Term, Open-Label Extension Study with CTP-543, an Oral Janus Kinase Inhibitor, in Patients with Moderate to Severe Alopecia Areata
  • Date and Time: Thursday, October 29, 2020, 3:00 – 3:15 pm Central European Time
  • Session: D1T03.3C: Late-Breaking News Session
  • Location: EADV Virtual Meeting. Registration is required to participate: https://eadvvirtualcongress.org/registration/

About CTP-543 and Alopecia Areata

CTP-543 is an oral selective inhibitor of Janus kinases JAK1 and JAK2. The U.S. Food and Drug Administration (FDA) has granted CTP-543 Breakthrough Therapy designation for the treatment of adult patients with moderate to severe alopecia areata and Fast Track designation for the treatment of alopecia areata.

The Company expects to begin Phase 3 evaluation of CTP-543 in the fourth quarter of 2020. Additional information on the upcoming trial is available on www.clinicaltrials.gov.

Alopecia areata is an autoimmune disease in which the immune system attacks hair follicles, resulting in partial or complete loss of hair on the scalp and body. Alopecia areata may affect up to 700,000 Americans at any given time1.

The scalp is the most commonly affected area, but any hair-bearing site can be affected alone or together with the scalp. Onset of the disease can occur throughout life and affects both women and men. Alopecia areata can be associated with serious psychological consequences, including anxiety and depression. There are currently no drugs approved by the FDA for the treatment of alopecia areata.

The FDA selected alopecia areata as one of eight new disease areas that it focused on under its Patient-Focused Drug Development Initiative (PFDDI) in 2016-2017. The goal of the PFDDI is to bring patient perspectives into an earlier stage of product development.

Following the FDA’s Patient-Focused Drug Development meeting held in September 2017 on alopecia areata, the FDA summarized the input shared by patients and patient representatives in a Voice of the Patient report. Additional information on the PFDDI is available online.

About Concert

Concert Pharmaceuticals is a clinical-stage biopharmaceutical company focused on applying its DCE Platform® (deuterated chemical entity platform) to create novel medicines designed to treat serious diseases and address unmet patient needs.

The Company’s approach starts with previously studied compounds, including approved drugs, in which deuterium substitution has the potential to enhance clinical safety, tolerability or efficacy. Concert’s pipeline of innovative medicines targets autoimmune diseases and central nervous systems (CNS) disorders.

For more information please visit www.concertpharma.com

1 Benigno M. Clinical, Cosmetic and Investigational Dermatology 2020

Concert Pharmaceuticals Announces CTP-543 Alopecia Areata Data Selected for Late-Breaker Oral Presentation at 2020 EADV Virtual Congress

Source

Previous Post

Alopecia Treatment Market

Global Alopecia Market

Global Alopecia Market Research Report 2020 Analysis, Demand, Insight, Key Players, Segmentation and Forecast to 2025

Eon Market Research has added a report titled “Global Alopecia (Hair Loss Treatment) Market Research Report 2020 Analysis, Demand, Insight, Key Players, Segmentation and Forecast to 2025”. The report will include the impact of COVID 19 and its impact on the growth of this industry during the forecast period.

The Alopecia (Hair Loss Treatment) market report offers the growth scenarios present globally as well as revenues of the overall market. The Global Alopecia (Hair Loss Treatment) market report thoroughly discusses robust growth prospects and prominent strategies implicated by several key players operating in the global market, which are likely to benefit the market growth and grab a leading position in terms of revenue in the Alopecia (Hair Loss Treatment) market.

In this report, the global Alopecia (Hair Loss Treatment) market is estimated at USD XX million in 2020 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2020 and 2025.

Geographically, this report is segmented into various key Regions

North America
Europe
China
Japan
Southeast Asia
India

Global Alopecia (Hair Loss Treatment) market competition

Shiseido
Rohto
Unilever
Taisho
Angfa
LOreal
Kaminomoto
Merck
Yanagiya Honten
Amorepacific
Procter and Gamble
Himalaya
Gerolymatos International
Merz Pharma
Leader Teck
Vasu Healthcare
VLCC
Ales Group
Shanxi Ante
Wansheng Pharmaceutical
Advanced Skin and Hair
Humanwell Healthcare
Topfond
Lifes2good
Bawang
YNK Pharmaceutical
Apollo
Jingxiutang
Rogaine
Marico

Based on product

Shampoos and Conditioners
Medicine Product

Based on the end users/applications

Men
Women

Global Alopecia Market Research Report 2020 Analysis, Demand, Insight, Key Players, Segmentation and Forecast to 2025

Source

Previous Post

Alopecia Treatment Market

Global Alopecia Market Insights

Global Alopecia Market Insights and Forecast to 2026

Alopecia market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Alopecia market will be able to gain the upper hand as they use the report as a powerful resource.

The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.

Segment by Type, the Alopecia market is segmented into

Oral treatment
Topical treatment
Other treatment

Segment by Application, the Alopecia market is segmented into

Male
Female

Regional and Country-level Analysis

The Alopecia market is analysed and market size information is provided by regions (countries).

The key regions covered in the Alopecia market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.

The report includes a country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.

Competitive Landscape and Alopecia Market Share Analysis

Alopecia market competitive landscape provides details and data information by players. The report offers a comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020.

It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Alopecia business, the date to enter into the Alopecia market, Alopecia product introduction, recent developments, etc.

The major vendors covered:

Lifes2good
Kirkland Signature
Johnson & Johnson
Dr Reddys Laboratories.
Cipla.
Alpecin.
Vitabiotics.
Sun Pharma.
Phyto Ales Group

Global Alopecia Market Insights and Forecast to 2026

Source

Previous Posts

Alopecia Treatment Market

Androgenic Alopecia Global Clinical Trials

Androgenic Alopecia Global Clinical Trials Review, H1, 2020

Summary

The clinical trial report, “Androgenic Alopecia Global Clinical Trials Review, H1, 2020″ provides an overview of Androgenic Alopecia Clinical trials scenario. This report provides top-line data relating to the clinical trials on Androgenic Alopecia.

The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type.

The report also provides prominent drugs for in-progress trials (based on a number of ongoing trials). Clinical Trial Reports are generated using proprietary database – Pharma – Clinical trials database.

Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision-making capabilities and helps to create an effective counter-strategy to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

– The report provides a snapshot of the global clinical trials landscape
– The report provides top-level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
– The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
– The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with a reason for unaccomplishment
– The Report provides enrollment trends for the past five years
– The report provides the latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to Buy

– Assists in formulating key business strategies with regards to investment
– Helps in identifying prominent locations for conducting clinical trials which saves time and cost
– Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
– Supports understanding of trials count and enrollment trends by country in global therapeutics market
– Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
– Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Androgenic Alopecia Global Clinical Trials Review, H1, 2020

Source

Previous Posts

Arena Starts Phase II Alopecia Areata Study on Etrasimod

Arena Starts Phase II Alopecia Areata Study on Etrasimod

Arena (ARNA) Starts Phase II Alopecia Areata Study on Etrasimod

Arena Pharmaceuticals, Inc. ARNA announced that it has dosed first patients in a phase II study to evaluate its key pipeline candidate — etrasimod — as a potential treatment for moderate-to-severe alopecia areata. The study will evaluate the 2mg dose of the candidate for efficacy and safety over 24 weeks.

The primary endpoint of the phase II study is the percent change in the Severity of Alopecia Tool (“SALT”) score from baseline. Data from the study is anticipated in 2021.

The candidate has demonstrated the potential to reduce inflammation and restore hair growth in earlier stage studies.

Shares of Arena have gained 50.5% year to date compared with the industry’s increase of 2.7%.

Alopecia areata is an autoimmune dermatologic condition that results in patchy non-scarring hair loss, usually affecting the scalp. There is no FDA approved drug presently available to treat this condition, which can lead to high levels of depression and anxiety in patients.

Pfizer PFE is another company developing an oral JAK3 inhibitor candidate, PF-06651600 for Alopecia areata in a pivotal study.

Apart from alopecia areata, Arena is developing etrasimod in other indications as well. The candidate is presently in late-stage development for ulcerative colitis (“UC”).

Arena is currently enrolling patients in two pivotal phase III studies — ELEVATE UC 52 and ELEVATE UC 12 — evaluating etrasimod for treating moderately-to-severely active UC.

A phase IIb study — ADVISE — is evaluating etrasimod in patients with atopic dermatitis (“AD”). Data from the study is expected later this year. Another phase IIb study — CULTIVATE — was initiated earlier this year to evaluate the candidate in Crohn’s disease. The company has plans to start a mid-stage study to evaluate the candidate for eosinophilic esophagitis, a gastro-intestinal disease by year-end.

Arena has another key pipeline candidate, olonarib. The phase II CAPTIVATE study is evaluating olaparib as a treatment for abdominal pain associated with irritable bowel syndrome. Data from the study is expected later this year.

We note that Arena is progressing well with its key pipeline candidates. However, the company will face stiff competition from multiple approved drugs in their targeted indications.

There are several drugs approved for treating UC including AbbVie’s ABBV multi-billion dollar drug, Humira. Sanofi/Regeneron’s REGN Dupixent is one of the top drugs approved for treating AD.

Moreover, olaparib, following potential approval, will compete with AbbVie/Ironwood Pharma’s Linzess.

Arena (ARNA) Starts Phase II Alopecia Areata Study on Etrasimod

Source

Previous Posts

Alopecia Treatment Market

Research on Alopecia Market

Research on Alopecia Market (impact of COVID-19) 2020-2026


In this study, we have issued the much-needed information on the Global Alopecia Market 2020 which covers detailed information about the Alopecia market size, Alopecia market trends, industrial dynamics and Alopecia market share.

Furthermore, it drops light on the series of instantly changing Alopecia market scenarios as well as the upcoming assessment of numerous factors that completely impacting the global Alopecia market report.

The research on the world Alopecia market illustrates the whole international market alongside a detailed analysis of the revenue growth and profitability of the Alopecia market.

The latest report on the worldwide Alopecia market represents a comprehensive understanding of the futuristic Alopecia market estimations, based on the historical and current predictions. It is considered to be the significant and professional document that especially focusing on the Alopecia market drivers, size, leading segments and topological zones.

Moreover, the report splits the global Alopecia market size by volume and value on the basis of product types, applications, well-established vendors and major geographies.

Pivotal industry players involved in this report are:

Lifes2good
Kirkland Signature
Johnson & Johnson
Dr Reddy’s Laboratories.
Cipla.
Alpecin.
Vitabiotics.
Sun Pharma.
Phyto Ales Group

The Global Alopecia market divided by product types:

Oral treatment
Topical treatment
Other treatment

Alopecia market segregation by application:

Male
Female

In the recent research document, we have listed out a wide range of business policies, mergers & acquisitions, collaborations, upcoming as well as trending innovative techniques. It also demonstrates systematic information and analysis related to the Global Alopecia market trends, growth factors, share, segments, challenges, opportunities and forecasts details from 2020 to 2026.

The global Alopecia market report showcases several factors that are driving the industrial growth and meanwhile, evaluates the present market scenario, insightful details and new updates about the corresponding segments involved in the Alopecia market report. It also sheds light on the price trends, demand and supply ratio, historical as well as forecasted industry data, and company shares of the top Alopecia market players by geography.

The report has been designed with the help of series of methodologies and essential techniques like SWOT analysis, Porter’s Five Forces analysis, graphical representation, pie charts and real-time analytics are helpful to add more precise and clear understanding about the Alopecia market-related facts and figures.

Research on Alopecia Market (impact of COVID-19) 2020-2026

Source

Previous Posts

Global Alopecia Treatment Industry Research Report

Alopecia Market

Alopecia Market

Market Summary

The Alopecia Market is expected to reach USD 12.99 Billion by 2026, according to a new report by Reports and Data. This can be mainly associated with the rising predominance of chronic disorders such as hyperthyroidism, hypothyroidism, acute stress disorder, lupus, and hypo pituitarism.

Moreover, increasing incidence of Hodgkin’s disease, Hashimoto’s disease, Addison’s disease, and celiac disease along with factors such as access to treatment quickly are expected to drive the market growth.

However, the high cost of treatment and adverse side effects is expected to restrain the growth. Also, changing lifestyle such as consumption of tobacco, an increase in the use of alcohol, and other associated products, growing stress levels, and the expanding population are expected to spur the market. Increasing disposable incomes coupled with expanding emphasis on aesthetic appearance are also likely to add to the demand for alopecia treatment worldwide.

Hair loss, also acknowledged as alopecia or baldness refers to a loss of hair from part of the head. The typical pattern of hair loss can vary from a small area to the entire body. Scarring or inflammation is not present. Hair loss in some people may cause psychological distress.

General types include female-pattern hair loss, male-pattern hair loss, alopecia areata, and a thinning of hair also known as telogen effluvium. The cause of male-pattern hair loss is a combination of male hormones and genetics, the purpose of female pattern hair loss is not clear, the use of alopecia areata is auto-immune, and the cause of telogen effluvium is mostly a psychological or physically stressful event.

The rising number of the introduction of new drugs, consumer disposable incomes, and the complementary initiatives taken by the relevant organizations namely, AHLA and NAAF, are the crucial factors for the North America region to account for the largest market share of 22.30% in 2018.

Key Coverage of the Report

Region and country wise statistics of Alopecia Market from the period 2016-2026. While 2016-2017 has been utilized as historical data, 2018 is considered the base year. 2019-2026 have been derived as forecasts.
Estimation of the market size along with historic and forecasted trend analysis.
Various Cure Types of Alopecia Market technique have been analyzed. Statistical analysis has been conducted on obtaining the individual share of these segments.
Regional up-coming Alopecia Market outlook.
Regional prevalence of the market has been mapped.
Demand and Supply GAP Analysis
Regional Competitors Pricing Strategy
Market share analysis of the top industry players
Strategic recommendations for the new entrants
Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
Strategic recommendations in key business segments based on the market estimations
Competitive landscaping mapping the key common trends
Company profiling with detailed strategies, financials, and recent developments.

Salient Trends of the Alopecia Market

The market is projected to grow at a CAGR of 1% in terms of value and reach USD 12.99 billion in 2026.
Based on disease type, the alopecia market is classified into androgenetic alopecia, alopecia areata (AA), and others. Androgenetic type led this market in 2018 with the largest revenue of USD 3.65 billion in 2018 and is expected to grow at a favorable rate over the forecast period.
Alopecia areata is an autoimmune skin disease identified by hair loss on the scalp, face, and other areas of the body. Alopecia areata is segmented into totalis, patchy, and universalis further.
The rising predominance of alopecia areata owing to autoimmune diseases such as diabetes, hyperthyroidism, and Down’s syndrome is expected to drive demand over the forecast period.
Increasing predominance coupled with rising awareness regarding aesthetic appeal and physical appearance is also assumed to drive market growth in the next few years.
Alopecia areata is expected to be the fastest-growing market with a CAGR of 5.2% during the forecast period.
Steroid injections may treat alopecia areata in the affected area, but these need to be continuously repeated to be effective. Hair loss is a common problem. The pattern of hair loss by age 50 affects about half of males and a quarter of females. About 1-2% of people develop alopecia areata at some point in time.
Male-Pattern Hair Loss (MPHL) or Androgenetic alopecia is associated with various medical conditions such as diabetes, coronary heart disease, obesity, prostate cancer, hypertension, and Polycystic Ovary Syndrome (PCOS).
Also, the availability of treatments such as oral treatments, licensed topical treatments involving the use of finasteride and minoxidil; and surgical procedures such as hair replacement and transplantation are expected to drive the market.
Laser treatments are also becoming common for non-invasive approach. Such non-invasive treatment approaches are also likely to drive the androgenetic segment.
The global Alopecia Market is growing at a rapid speed owing to the increase in stress and changed lifestyle.
The market can be classified into home care settings and dermatology clinics, based on application. Dermatology clinics account for the largest market share of 54.24% in 2018 and are anticipated to grow at a fruitful rate over the forecast period.
Dermatology clinics coupled with innovative technologies and prescription hair care products help many affected individuals fight their condition.
Consultation with dermatologists is regarded as the best option for the treatment, as they prescribe suitable medication or therapy for effective results. These factors are responsible for the high need for dermatology clinics for hair loss treatment.
On the other hand, treatment in home care settings is expected to grow at a rate of 5.1% during the forecast period.
Prescription medicine segment is anticipated to grow owing to increasing disposable income and quickly changing lifestyle. Finasteride and Corticosteroids are some of the majorly prescribed medications.
Based on the sales distribution, the market is segmented into prescription-based medications or treatment devices and Over the Counter (OTC).
Sale of prescription products account for the larger market share of 68.85% in 2018 and is estimated to reach USD 5.95 billion by 2026.
The OTC segment is expected to grow at a rate of 5.1% during the forecast period.
Increasing R&D efforts to improve treatments, FDA approvals obtained for certain products and strategic initiatives taken by the key players, are the primary competitive strategies paving the way for market expansion.
In April 2016, Johnson & Johnson announced the launch of a new global healthcare initiative to implement healthcare solutions, in Africa.
The developing prosperity of countries such as Indonesia, Taiwan, China, and India is inviting new international ventures in these countries thereby leading to the growth of various industries in the APAC region.

Companies considered and profiled in this market study

Cipla Inc., Johnson and Johnson AG, Transitions Hair Pty Ltd., Sun Pharmaceutical Industries Ltd., Merck & Co., Inc.,  Cirrus Hair Centers, Lexington International LLC,  Vita-Cos-Med Klett-Loch GmbH, Follica, Inc., and Capillus.

Market-O-Nomics

Rising demand for low-cost treatment, growing awareness regarding adverse effects of prescribed drugs, and the increasing availability of options are spurring the need for OTC products.
Moreover, a surge in the number of FDA-approved OTC products for hair loss treatments is additionally expanding their demand. Some of the FDA-approved OTC products for hair loss treatment are Oscar Blandi hair lift instant thickening and strengthening serum and Keranique hair regrowth system.
In 2018, the dominant gender segment for the alopecia market is women that accounts for the larger market share of 56.48%. The growing awareness amongst women about alopecia and the importance laid upon appearance by them are the key drivers of this segment.
Due to the predominance of a vast number of new entrants, established manufacturers, and suppliers in the market, the industry is extremely competitive.
Asia Pacific is forecasted to witness the fastest CAGR of 5.4% during the forecast period. A vast population suffering from alopecia and growing awareness about the available therapeutic options are the key growth drivers.
Economic development coupled with continually increasing per capita healthcare investment in emerging countries such as India, China, and Singapore is expected to create high growth opportunities.
Innovations and technological trends in treatment, evolving healthcare expenditures, and increased healthcare facilities are expected to drive the growth further.

Segments Covered in the report:

This report forecasts revenue growth at a global, regional & country level, and provides an analysis on the industry trends in each of the sub-segments from 2018 to 2026.

For the purpose of this study, Reports and Data have segmented the global Alopecia Market on the basis of Disease, Gender, application, Sales distribution and region:

Disease Outlook (Revenue, USD Million; 2016-2026)

Alopecia Areata
Androgenetic Alopecia
Others

Sales distribution Outlook (Revenue, USD Million; 2016-2026)

Prescriptions
OTC

Application Outlook (Revenue, USD Million; 2016-2026)

Homecare Settings
Dermatology Clinics

Gender Outlook (Revenue, USD Million; 2016-2026)

Female
Male

Regional Outlook (Revenue, USD Million; 2016-2026)

North America
U.S.
Europe
Germany
UK
Asia Pacific
China
India
Southeast Asia
Latin America
Brazil
Middle East & Africa

Source

Previous Posts